Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605178 | 0.88 | PKM (0.61) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL11877 | 0.87 | PKM (0.62) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL7602391 | 0.81 | PKM (0.62) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL12114 | 0.81 | PABPC1 (0.66) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL14802 | 0.80 | PKM (0.60) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL12597657 | 0.79 | PKM (0.63) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL14840 | 0.78 | PKM (0.62) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL12112 | 0.78 | PKM (0.76) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL14809 | 0.78 | ALDH1A1 (0.67) | PKMHTTALDH1A1MAPTGFER | |
| SCHEMBL7602357 | 0.78 | PKM (0.57) | PKMHTTALDH1A1MAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |